Navigation Links
Zeus Announces Product Name Changes
Date:2/10/2009

Zeus announces new product names that better reflect the unique properties and industry-leading characteristics of these products.

Orangeburg, SC (PRWEB) February 11, 2009 -- Zeus, Inc. announces new product name changes that signify its commitment to innovation and quality. The selected products are unaltered in composition and processing. They remain the same quality products that Zeus customers have come to expect and trust.

New brand names are as follows:

  • New trademarked product Aeos™, formerly known as ePTFE, is a micro-porous material that is medically implantable and has a low coefficient of friction. The new brand name Aeos was coined after the word "eon" to suggest the material's durability over an extended period of time.

  • New trademarked product Impactiv™, formerly known as Lubricious PEEK™, is a new version of PEEK tubing and can be used anywhere PEEK is used with a need for lower coefficient of friction. The material's new name suggests the product's excellent impact resistance.

  • New trademarked product Absorv™, formerly known as Zeus Biomaterial, receives its new brand name from its distinctive absorptive quality. These absorbable polymers have generated an extreme amount of interest due to their unique ability to perform vital functions in the body and safely absorb after they have carried out their function.

  • New trademarked product DuaTem™, formerly known as Hytem, is a flexible alternative to Ultem and is capable of operating at both high and low service temperatures. The new brand name reflects the dual properties of the product.

About Zeus, Inc.:
Zeus, Inc. is headquartered in Orangeburg, SC USA. Zeus is a world leader in the design and production of high-performance polymer tubing used in demanding applications; operating multiple facilities in North America and internationally. Zeus products and services are preferred by companies in medical, automotive, electrical, fluid handling, and mechanical markets. For more information, visit www.zeusinc.com.

###

Read the full story at http://www.prweb.com/releases/2009/02/prweb1998804.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... at the Pennsylvania Convention Center and will showcase its product’s latest features from ... also be presenting a scientific poster on Disrupting Clinical Trials in The Cloud ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):